Real-World Outcomes of Oral VEGFR Tyrosine Kinase Inhibitor-Containing Therapy in Unresectable Malignant Mesothelioma: A Single-Center Retrospective Study
Cancers · 04.11.2026 · 18 (21) · 3541
DOI: 10.3390/cancers18213541 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 04.11.2026. Verfasst von Zheng Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Molecular Oncology, Beijing Key Laboratory, CAMS Key Laboratory of Translational Research on Lung Cancer, Department of Medic…. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Noncommunicable Chronic Diseases-National Science and Technology Major Project, National High Level Hospital Clinical Research Funding, CAMS Innovation Fund for Medical Sciences (CIFMS).
Abstract (Originalsprache)
Background
Systemic treatment choices after failure of standard therapy are limited for malignant mesothelioma. Oral vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) have been incorporated into salvage treatment strategies, but real-world evidence regarding their effectiveness and safety remains scarce.
Methods
We retrospectively analyzed a single-center cohort comprising patients with pathologically confirmed malignant mesothelioma treated at Cancer Hospital, Chinese Academy of Medical Sciences/National Cancer Center between 1 April 2017 and 16 March 2023. Patients with unresectable disease who received a VEGFR-TKI-containing regimen and had sufficient clinical follow-up for outcome assessment were included. Progression-free survival (PFS) served as the primary endpoint. Objective response rate (ORR), disease control rate (DCR), overall survival (OS) from VEGFR-TKI initiation, and recorded adverse events were included as secondary endpoints.
Results
The cohort comprised 48 patients, with a median follow-up of 24.0 months. The Kaplan–Meier estimated median PFS was 4.8 months (95% CI, 2.9–8.8), and median OS from VEGFR-TKI initiation was 17.9 months (95% CI, 13.5–not estimable). Among 39 response-evaluable patients, 6 achieved partial response, 20 had stable disease, and 13 had progressive disease as their best overall response, yielding an ORR of 15.4% and a DCR of 66.7%. Two patients remained progression-free for more than 24 months. Grade 3 adverse events in the records included hematuria, hypertension, and nausea/vomiting; no grade 4 or grade 5 adverse event was documented.
Conclusions
VEGFR-TKI-containing therapy was associated with clinically relevant disease control in unresectable malignant mesothelioma, with durable benefit observed in a small subset of patients. These observations warrant further evaluation of VEGFR-TKI-based salvage strategies in larger multicenter cohorts.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Molecular Oncology, Beijing Key Laboratory, CAMS Key Laboratory of Translational Research on Lung Cancer, Department of Medical Oncology, National Cancer Center/National Clinical Research Center…
ORCID-Profile: Jian-Chun Duan, Hua Bai, Jie Wang
Förderung
- Noncommunicable Chronic Diseases-National Science and Technology Major Project
- National High Level Hospital Clinical Research Funding
- CAMS Innovation Fund for Medical Sciences (CIFMS)
Zitieren
APA
Liu, Z., Zhong, J., Wan, R., Duan, J. C., Wang, Z. J., Bai, H., & Wang, J. (2026). Real-World Outcomes of Oral VEGFR Tyrosine Kinase Inhibitor-Containing Therapy in Unresectable Malignant Mesothelioma: A Single-Center Retrospective Study. Cancers, 18(21), 3541. https://doi.org/10.3390/cancers18213541
Vancouver
Liu Z, Zhong J, Wan R, Duan JC, Wang ZJ, Bai H, et al. Real-World Outcomes of Oral VEGFR Tyrosine Kinase Inhibitor-Containing Therapy in Unresectable Malignant Mesothelioma: A Single-Center Retrospective Study. Cancers. 2026;18(21):3541. doi:10.3390/cancers18213541
BibTeX
@article{Liu2026,
author = {Liu, Zheng and Zhong, Jia and Wan, Rui and Duan, Jian-Chun and Wang, Zhi-Jie and Bai, Hua and Wang, Jie},
title = {Real-World Outcomes of Oral VEGFR Tyrosine Kinase Inhibitor-Containing Therapy in Unresectable Malignant Mesothelioma: A Single-Center Retrospective Study},
journal = {Cancers},
year = {2026},
volume = {18},
number = {21},
pages = {3541},
doi = {10.3390/cancers18213541}
}
EUVIMED